CD274 and urinary bladder carcinoma: According to the National Comprehensive Cancer Network’s ‘Clinical Practice Guidelines in Oncology’ for bladder cancer, the use of PD-1/PD-L1 blocking antibodies such as Atezolizumab [37, 38], Nivolumab [39], Avelumab [40], and Pembrolizumab [41, 42] is recommended from a clinical perspective.